Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Film Dosimetry | 3 | 2017 | 11 | 1.160 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2017 | 36 | 1.140 |
Why?
|
| Phantoms, Imaging | 4 | 2017 | 189 | 1.000 |
Why?
|
| Radiosurgery | 2 | 2014 | 66 | 0.820 |
Why?
|
| Water | 2 | 2015 | 230 | 0.790 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 30 | 0.630 |
Why?
|
| Quality Assurance, Health Care | 2 | 2017 | 177 | 0.610 |
Why?
|
| Radiation Dosage | 3 | 2018 | 419 | 0.600 |
Why?
|
| Neoplasms | 2 | 2017 | 1667 | 0.480 |
Why?
|
| Tumor Burden | 1 | 2014 | 132 | 0.480 |
Why?
|
| Algorithms | 3 | 2017 | 1196 | 0.470 |
Why?
|
| Radiometry | 2 | 2011 | 64 | 0.460 |
Why?
|
| Radiotherapy Dosage | 5 | 2017 | 125 | 0.390 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 371 | 0.370 |
Why?
|
| Fracture Healing | 1 | 2018 | 29 | 0.160 |
Why?
|
| Femoral Fractures | 1 | 2018 | 45 | 0.160 |
Why?
|
| Femur | 1 | 2018 | 113 | 0.150 |
Why?
|
| Osteogenesis | 1 | 2018 | 152 | 0.140 |
Why?
|
| Radiation | 1 | 2016 | 7 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2016 | 24 | 0.140 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 1851 | 0.140 |
Why?
|
| Radiation Injuries | 2 | 2015 | 97 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.140 |
Why?
|
| Apoptosis | 4 | 2015 | 1641 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2015 | 652 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.120 |
Why?
|
| Catalase | 1 | 2015 | 85 | 0.120 |
Why?
|
| Hematopoiesis | 1 | 2015 | 108 | 0.120 |
Why?
|
| Complement C3d | 1 | 2014 | 10 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2014 | 35 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 511 | 0.120 |
Why?
|
| Lymphoma | 1 | 2014 | 116 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2015 | 706 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 268 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2015 | 219 | 0.110 |
Why?
|
| Antioxidants | 1 | 2015 | 304 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 756 | 0.100 |
Why?
|
| Imidazoles | 1 | 2013 | 175 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2013 | 112 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2011 | 12 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2014 | 622 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 206 | 0.100 |
Why?
|
| Health Physics | 1 | 2011 | 14 | 0.100 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2011 | 5 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 231 | 0.100 |
Why?
|
| Stereotaxic Techniques | 1 | 2011 | 35 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 448 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 1173 | 0.090 |
Why?
|
| Calibration | 1 | 2011 | 73 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.090 |
Why?
|
| Posture | 1 | 2011 | 107 | 0.090 |
Why?
|
| Radiology | 1 | 2011 | 97 | 0.090 |
Why?
|
| Humans | 12 | 2017 | 68618 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.080 |
Why?
|
| X-Ray Intensifying Screens | 1 | 1988 | 16 | 0.080 |
Why?
|
| Breast | 1 | 1988 | 137 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 1988 | 208 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 24 | 0.070 |
Why?
|
| Mammography | 1 | 1988 | 310 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 20 | 0.060 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 47 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 62 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2005 | 79 | 0.060 |
Why?
|
| Time Factors | 4 | 2018 | 4655 | 0.060 |
Why?
|
| Radiation, Ionizing | 2 | 2015 | 37 | 0.060 |
Why?
|
| Brain | 1 | 2014 | 2176 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 300 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 84 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2083 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 2689 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1174 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2018 | 50 | 0.040 |
Why?
|
| Bone Nails | 1 | 2018 | 32 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 20881 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2018 | 33 | 0.040 |
Why?
|
| Bone Plates | 1 | 2018 | 49 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 2791 | 0.040 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 5 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 52 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2016 | 233 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 129 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Male | 6 | 2018 | 37321 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 219 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1536 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 86 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 6 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 432 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 35 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 499 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1040 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 190 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 901 | 0.030 |
Why?
|
| Complement Inactivating Agents | 1 | 2014 | 56 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 51 | 0.030 |
Why?
|
| Complement Activation | 1 | 2014 | 145 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 97 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 8474 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2014 | 201 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.030 |
Why?
|
| Societies | 1 | 2011 | 15 | 0.020 |
Why?
|
| Particle Accelerators | 1 | 2011 | 10 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 1992 | 90 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2011 | 9 | 0.020 |
Why?
|
| Quality Control | 1 | 2011 | 81 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2550 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1992 | 205 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1992 | 163 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 597 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 500 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2673 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 214 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2006 | 4848 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|
| Middle Aged | 4 | 2011 | 21147 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Female | 5 | 2011 | 38074 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2077 | 0.020 |
Why?
|
| Iridium Radioisotopes | 1 | 2005 | 11 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 778 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 64 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 540 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 800 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1056 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 1038 | 0.010 |
Why?
|
| Aged | 3 | 2006 | 14862 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3259 | 0.010 |
Why?
|
| South Carolina | 1 | 2006 | 2752 | 0.010 |
Why?
|
| United States | 1 | 2011 | 7367 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7029 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2006 | 7277 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1992 | 33 | 0.010 |
Why?
|
| Immune System | 1 | 1992 | 63 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 242 | 0.010 |
Why?
|
| Adult | 2 | 2005 | 21403 | 0.010 |
Why?
|
| Cross Infection | 1 | 1992 | 195 | 0.010 |
Why?
|
| Risk Factors | 1 | 1992 | 5731 | 0.000 |
Why?
|
| Adolescent | 1 | 1992 | 8912 | 0.000 |
Why?
|